Company Growth (employees)
Aimmune Therapeutics was founded in 2011 and is headquartered in Brisbane, US
Aimmune Therapeutics Office Locations
Aimmune Therapeutics has offices in Brisbane and Greater London
Brisbane, US (HQ)
200 8000 Marina Blvd
Greater London, GB
344-354 Grays Inn Rd
Aimmune Therapeutics Data and Metrics
Aimmune Therapeutics Financial Metrics
USD
Net income (Q1, 2017) | (25.9 m) |
EBIT (Q1, 2017) | (26.3 m) |
Market capitalization (18-Aug-2017) | 957.9 m |
Cash (31-Mar-2017) | 78.7 m |
Aimmune Therapeutics's current market capitalization is $957.9 m.
| USD | FY, 2015 | FY, 2016 |
|---|---|---|
R&D expense | 19.8 m | 54.6 b |
General and administrative expense | 16.2 m | 26.9 b |
Operating expense total | 36 m | 81.5 b |
EBIT | (36 m) | (81.5 b) |
Interest expense | (36 k) | |
Interest income | 217 k | |
Pre tax profit | (35.8 m) | (80.8 b) |
Net Income | (35.8 m) | (80.8 m) |
| USD | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|
R&D expense | 3.1 m | 3.9 m | 10 m | 11.8 m | 15.9 m | 17.4 m |
General and administrative expense | 4.2 m | 5.2 m | 5.7 m | 6.5 m | 6.4 m | 8.9 m |
Operating expense total | 7.4 m | 9 m | 15.7 m | 18.3 m | 22.2 m | 26.3 m |
EBIT | (7.4 m) | (9 m) | (15.7 m) | (18.3 m) | (22.2 m) | (26.3 m) |
Interest expense | (24 k) | (25 k) | ||||
Interest income | 1 k | 33 k | 215 k | 231 k | ||
Net Income | (9 m) | (15.5 m) | (18.1 m) | (22.1 m) | (25.9 m) |
| USD | FY, 2015 | FY, 2016 |
|---|---|---|
Cash | 76.7 m | 124 m |
Inventories | 5.6 m | 2.7 m |
Current Assets | 197.5 m | 251.7 m |
PP&E | 2.7 m | 10.4 m |
Total Assets | 212.4 m | 298.8 m |
Accounts Payable | 1.9 m | 1.4 m |
Current Liabilities | 5.1 m | 11.5 m |
Total Liabilities | 12.8 m | |
Additional Paid-in Capital | 259.7 m | 420.2 m |
Retained Earnings | (53.3 m) | (134.2 m) |
Total Equity | 206.3 m | 286 m |
Financial Leverage | 1 x | 1 x |
| USD | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|
Cash | 58.5 m | 112.7 m | 65 m | 74.4 m | 76.9 m | 78.7 m |
Current Assets | 60.6 m | 217.8 m | 185.2 m | 172.8 m | 152.6 m | 248.9 m |
PP&E | 1.3 m | 1.8 m | 3.7 m | 7 m | 9 m | 11.1 m |
Total Assets | 62.1 m | 222.8 m | 199.9 m | 185.7 m | 173.7 m | 276.3 m |
Accounts Payable | 309 k | 1 m | 1.8 m | 1.3 m | 1.5 m | 1.7 m |
Current Liabilities | 3.3 m | 3.1 m | 5.3 m | 5.8 m | 11.8 m | 10.2 m |
Additional Paid-in Capital | 2.5 m | 256.2 m | 262.2 m | 265.5 m | 269.6 m | 424.9 m |
Retained Earnings | (28.3 m) | (37.3 m) | (68.9 m) | (87 m) | (109.1 m) | (160 m) |
Total Equity | 58 m | 218.9 m | 193.4 m | 178.5 m | 160.5 m | 264.7 m |
Financial Leverage | 1.1 x | 1 x | 1 x | 1 x | 1.1 x | 1 x |
| USD | FY, 2015 | FY, 2016 |
|---|---|---|
Net Income | (35.8 m) | (80.8 m) |
Depreciation and Amortization | 115 k | 534 k |
Inventories | 4 m | |
Accounts Payable | 1.1 m | (994 k) |
Cash From Operating Activities | (35.7 m) | (56.6 m) |
Purchases of PP&E | (1.7 m) | (7.7 m) |
Cash From Investing Activities | (125.2 m) | (43.9 m) |
Cash From Financing Activities | 235.3 m | 147.8 m |
| USD | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|
Net Income | (9 m) | (15.5 m) | (18.1 m) | (22.1 m) | (25.9 m) | |
Accounts Payable | 309 k | 1 m | 1.8 m | 1.3 m | 1.5 m | 1.7 m |
| Y, 2017 | |
|---|---|
Financial Leverage | 1 x |
